News >

Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma

Danielle Bucco
Published: Friday, Nov 03, 2017

Alfred L. Garfall, MD
Alfred L. Garfall, MD
The multiple myeloma paradigm continues to expand and evolve as long-term results become available, with constantly changing roles for stem cell transplant, immunomodulatory agents, and maintenance therapy and the imminent introduction of chimeric antigen receptor (CAR)-modified T-cell therapies, explained Alfred L. Garfall, MD, MS.

The immunomodulatory agent lenalidomide (Revlimid) is a key component of triplet therapy, when used in combination with bortezomib (Velcade) or carfilzomib (Kyprolis) and dexamethasone. Findings from the SWOG-S0777 study1 showed a 29% reduction in the risk of death with lenalidomide, bortezomib, and dexamethasone versus lenalidomide and dexamethasone alone (HR, 0.71; 95% CI, 0.52-0.96; P = .025).

Even with these novel regimens, there still remains a role for autologous stem cell transplant (ASCT), Garfall noted, especially when used with maintenance therapy. In findings from a meta-analysis,2 maintenance lenalidomide following ASCT reduced the risk of death by 25% compared with placebo or observation with (HR, 0.75; 95% CI, 0.63-0.90; P = .001).

“This response is [present] despite the slight increased risk of second primary malignancies with use of lenalidomide in the maintenance setting,” said Garfall, assistant professor of medicine at the Hospital of the University of Pennsylvania.

In an interview during the 2017 OncLive® State of the Science Summit on Hematologic MalignanciesTM, Garfall, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant. He also highlighted the importance of aggressive therapy for patients with renal insufficiency.

OncLive®: Can you please provide an overview of your presentation?

Garfall: I focused on data that have come out over the last few years for managing first-line therapy for multiple myeloma that we believe is best. The first systemic therapy that patients receive are consolidation strategies, stem cell transplants, and maintenance therapies to attempt to maintain a response.

There have been several new regimens that have been developed over the last decade incorporating agents such as lenalidomide, bortezomib, and carfilzomib that have shown potent initial responses. In the last couple of years, we started to get some of the long-term data from the studies. We are comparing them to one another to understand whether the initial response rates translate into long-term survival benefits compared with standard regimens.

We focused on the SWOG-S0777 study that compared lenalidomide, bortezomib, and dexamethasone to lenalidomide and dexamethasone. This study is comparing a 3-drug therapy to a 2-drug therapy. Not only was there a slightly higher response rate with the 3-drug therapy, but there was a significant improvement in overall survival (OS), as well. With those results, this treatment is moving forward to being our standard approach for early diagnosed multiple myeloma, as opposed to the previous approach which was to start with 2-drug regimens and then move on to 3-drug regimens in patients with aggressive disease who were not responding.

There are data that have come out recently that continue to support the role of high-dose ASCT in the first-line therapy for multiple myeloma showing that, even with modern therapy, there continues to be a PFS and OS benefit associated with this approach.

This treatment is followed by low-dose lenalidomide maintenance therapy.

In the last year, the meta-analyses of long-term follow-up within 3 large clinical trials compared maintenance therapy with placebo or no maintenance therapy showing that there is an OS benefit to maintenance lenalidomide.

With these novel options, what role will transplant have in the future of this landscape?

There will still be a role for transplant. If transplant was 1 out of 100 therapies that we have for this disease, it would be easy to set it aside. However, as it is only 1 of 12 or so therapies, it will continue to play a role despite the inconvenience and adverse events. For the short-term, most patients do get through it with proper supportive care and recovery.

Until we discover a similar R-CHOP therapy for myeloma, where we find just the right combination of novel medications that can potentially cure some patients, there will be a role for transplant because it is an active therapy. As long as patients are still relapsing, we should be trying to give them every active therapy, in some form, over the course of their disease until that supply of new therapies becomes so plentiful that transplant is just one of many alternatives.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication